H.R. 9708House117th Congress (2021-2023)In Committee

Fixing Administrations Unethical Corrupt Influence Act

Introduced January 3, 2023

AI-Generated Summary

Updated February 8, 2026 at 7:01 PM UTC

The Fixing Administrations Unethical Corrupt Influence Act aims to prevent conflicts of interest by barring former senior officials of certain federal health agencies from influencing vaccine companies. It stops them from joining boards of vaccine developers or researchers and from profiting from vaccine‑related patents. The law applies to former top officials of the NIH, FDA, and CDC and to entities that make or study licensed or emergency‑use vaccines.

Key Provisions

  • Prohibits any former top official of the NIH, FDA, or CDC from serving as an officer or board member of any corporation, association, or entity that directly manufactures or researches a covered vaccine.
  • Defines "covered vaccines" as those licensed under the Public Health Service Act or authorized for emergency use under the FD&C Act, and defines "top official" as federal employees at GS‑13 level or higher, or those with authority over vaccine authorizations.
  • Bars top officials from owning, profiting from, or applying for patents on vaccines or related medical treatments, requiring them to assign such patents before taking federal office and prohibiting reassignment after service.
  • Sets the prohibitions to take effect for individuals whose federal employment ends on or after the law’s enactment.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
HouseIntro Referral Latest Action

Referred to the House Committee on the Judiciary.

January 3, 2023

View full timeline
HouseIntro Referral

Introduced in House

January 3, 2023

HouseIntro Referral

Referred to the House Committee on the Judiciary.

January 3, 2023

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued January 3, 2023

I

117th CONGRESS

2d Session

H. R. 9708

IN THE HOUSE OF REPRESENTATIVES

January 3, 2023

Mr. Gohmert introduced the following bill; which was referred to the Committee on the Judiciary

A BILL

To amend title 18, United States Code, to prohibit former employees of covered health agencies from serving on the board of entities involved in development and research of covered vaccines, and for other purposes.

1.

Short title

This Act may be cited as the Fixing Administrations Unethical Corrupt Influence Act or the FAUCI Act.

2.

Prohibition against service by former employees of covered health agencies on boards of entities involved in development and research of vaccines

(a)

Prohibition against service on boards of entities

Title 18, United States Code, is amended by inserting after section 207 the following new section:

207A.

Prohibition against service by former employees of covered health agencies on boards of entities involved in development and research of vaccines.

(a)

Prohibition against service by former employees of covered health agencies on boards of entities involved in development and research of vaccines

Any person who is a top official of a covered health agency of the United States, and who, after the termination of his or her service or employment with the United States, serves as an officer or member of the board of any association, corporation, or entity that directly manufactures or researches covered vaccines shall be punished as provided in section 216 of this title.

(b)

Definitions

In this section:

(1)

Covered health agency

The term covered health agency means any of the following:

(A)

The National Institutes of Health.

(B)

The Food and Drug Administration.

(C)

The Centers for Disease Control and Prevention.

(2)

Covered vaccines

The term covered vaccine means—

(A)

a vaccine licensed under section 351 of the Public Health Service Act; or

(B)

a vaccine authorized for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act.

(3)

Top official

The term top official means—

(A)

any officer or employee in the executive branch who occupies a position classified at or above GS–13 of the General Schedule or, in the case of positions not under the General Schedule, for which the rate of basic pay is equal to or greater than the minimum rate of basic pay payable for GS–13 of the General Schedule; or

(B)

any employee of the Federal Government who directly or indirectly has input or any authority to determine or help determine the authorization for use or emergency use authorization of vaccines.

.

(b)

Table of chapters

Chapter of 11 of title 18, United States Code, is amended by inserting after the item relating to section 207 the following:

Sec. 207A. Prohibition against service by former employees of covered health agencies on boards of entities involved in development and research of vaccines.

.

(c)

Effective date

The amendments made by this section shall apply with respect to an individual whose service or employment with the United States terminates on or after the date of the enactment of this Act.

3.

Prohibition against ownership or financial interest in certain patents

(a)

Amendment

Section 208 of title 18 is amended by adding at the end the following new subsection:

(e)

Prohibition against ownership or financial interest in certain patents

(1)

In general

A person who is a top official may not own or profit from a covered patent (or any right or interest in a covered patent), submit an application for a covered patent, (or be included in the application for a covered patent)—

(A)

in the case of a vaccine or medical treatment invented by the person during the course of employment as a top official, at any point after becoming a top official;

(B)

in the case of a vaccine or medical treatment invented by the person before or outside the course of employment as a top official, at any point after becoming a top official;

(C)

in the case of a covered patent for which the top official was issued a patent before or outside the course of employment as a top official, at any point after becoming a top official; and

(D)

in the case of a covered patent owned by the top official or a covered patent in which the top official has any right or interest in before the course of employment as a top official, at any point after becoming a top official.

(2)

Assignment of prior patents

(A)

In general

To comply with paragraph (1), a person who is a top official may assign grant, or convey ownership of a covered patent, or any rights or interest in a covered patent, to another person, before becoming a top official.

(B)

After Federal service

In the case of a covered patent described under paragraph (1)(A), any rights or interest in the patent that are assigned, granted, or conveyed under subparagraph (A), may not be reassigned to the top official after such individual ceases to be a top official.

(3)

Definitions

In this subsection:

(A)

Covered patent

The term covered patent means a patent issued by the United States for a vaccine or medical treatment.

(B)

Top official

The term top official means—

(i)

Each officer or employee in the executive branch who occupies a position classified at or above GS–13 of the General Schedule or, in the case of positions not under the General Schedule, for which the rate of basic pay is equal to or greater than the minimum rate of basic pay payable for GS–13 of the General Schedule; or

(ii)

any employee of the Federal Government who directly or indirectly has input or any authority to determine or help determine the authorization for use or emergency use authorization of vaccines.

.

(b)

Prior patents

(1)

In general

To comply with section 208 of title 18, United States Code, as added by subsection (a), a top official that owns, or is profiting from, any patent for a vaccine or medical treatment (or any right or interest in such a patent), may assign grant, or convey ownership of the patent, or any rights or interest in the patent, to another person, not later than 6 months after the date of the enactment of this Act.

(2)

After Federal service

In the case of patent described under section 208(e)(1)(A) of title 18, United States Code, as added by subsection (a), any rights or interest in the patent that are assigned, granted, or conveyed under paragraph (1), may not be reassigned, to the top official after such individual ceases to be a top official.